Scandinavian ChemoTech

During the trials, the equine team, led by Drs. Michael Hewetson and Andy Fiske-Jackson, has evaluated the TSE on patients suffering from both melanocytic tumours and sarcoids.

Although the follow-up period is not yet complete, the team is pleased with the overall clinical outcomes and the objective response achieved so far. Importantly,  in some cases, the team was able to administer the TSE therapy without the requirement for general anesthesia. The treatments were conducted using nerve blocks and standing sedation, thus mitigating against the inherent risks of general anaesthesia. This represents a notable advancement in the approach to patient care for horses undergoing electroporation.

Despite the clear demonstration of TSE's ability to bring about clinical breakthroughs with its less destructive approach to treating cancer in both humans and animals, Vetiqure are committed to persisting in their research efforts. By doing so, they will gain a deeper understanding of the biological and physical impact this treatment has on cancer cells and the tumour microenvironment and in particular its immune component. These endeavors are vital to continue to further knowledge and pave the way for more effective TSE-based combination therapies.

"It is of utmost importance that we collaborate closely with esteemed academia and veterinarians to further our clinical advancements and disseminate novel TSE guidelines and protocols. Hence, the potential establishment of a Centre of Excellence at RVC holds significance for Vetiqure, as well as for equine veterinarians worldwide, seeking to incorporate TSE therapy in the treatment of horses afflicted with sarcoids or malignant tumours", says Dr. Suhail Mufti, Medical Director at ChemoTech and Vetiqure.

"We have been trialling TSE here at the RVC for the past 6 months, and have been impressed with the response rates in the horses that we have treated thus far. Further work needs to be done before we are able to publish our findings, however, the initial results have been promsing. This innovative treatment modality has the potential to significantly improve the welfare of horses with tumours that are not amenable to surgical excision, and we are optimistic for the future. We look forward to continue working with Vetiqure to refine and optimize this technology further", says Dr. Michael Hewetson, Associate Professor of Equine Internal Medicine at RVC Equine department.

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Certified Adviser: Redeye AB, Phone: +46 (0)8 - 121 576 90

E-mail: certifiedadviser@redeye.se

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-08-2023 at 11:30 CET.

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.